CLINICAL TRIALS PROFILE FOR EFINACONAZOLE
✉ Email this page to a colleague
All Clinical Trials for efinaconazole
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02812771 ↗ | Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis | Completed | Bausch Health Americas, Inc. | Phase 4 | 2016-08-04 | Safety and Pharmacokinetics (PK) of a once daily topical application of efinaconazole in the treatment of pediatric subjects with mild to severe onychomycosis of the toenails. |
| NCT02812771 ↗ | Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis | Completed | Valeant Pharmaceuticals International, Inc. | Phase 4 | 2016-08-04 | Safety and Pharmacokinetics (PK) of a once daily topical application of efinaconazole in the treatment of pediatric subjects with mild to severe onychomycosis of the toenails. |
| NCT03098615 ↗ | Study Evaluating the Effect of Jublia on Dermatophytomas | Completed | University of Alabama at Birmingham | Phase 4 | 2015-09-01 | This study will examine how Jublia affects dermatophytomas, which are difficult to treat with other therapeutic options. |
| NCT03110029 ↗ | Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish | Completed | University of Alabama at Birmingham | Phase 4 | 2015-09-01 | This study will test how well efinaconazole solution (Jublia) works to treat toenail fungal infections in patients who wear polish compared to those who do not. |
| NCT03168841 ↗ | Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients | Completed | Western University of Health Sciences | Phase 3 | 2017-06-06 | Onychomycosis, a common pathology of the toenails, is even more prevalent among diabetic subjects. Nearly 26 million Americans suffer from diabetes, and approximately one-third of subjects with diabetes have toenail onychomycosis. Numerous studies have addressed the efficacy and safety of both topical and oral antifungal treatment options for onychomycosis in diabetic subjects. However, no study to date has specifically addressed the efficacy and safety of efinaconazole among diabetic subjects. The objective of this noncomparative, uncontrolled study is to determine the efficacy of topical efinaconazole 10% for toenail onychomycosis among subjects with diabetes mellitus. Specific indicators to measure efficacy of treatment will be the mycological cure rate, complete cure rate, and treatment success. Furthermore, an additional goal of the study is to gain knowledge of safety in the setting of a cohort of diabetic subjects |
| NCT03280927 ↗ | Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis | Completed | Dong-A ST Co., Ltd. | Phase 4 | 2017-11-10 | The antifungal efficacy and safety of Jublia® topical solution will be assessed through an administration for 48 weeks to patients diagnosed with a mild or moderate onychomycosis due to dermatophyte. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for efinaconazole
Condition Name
Clinical Trial Locations for efinaconazole
Trials by Country
Clinical Trial Progress for efinaconazole
Clinical Trial Phase
Clinical Trial Sponsors for efinaconazole
Sponsor Name
